Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine.

ABSTRACT:

Objectives

The effect of rifapentine plus isoniazid on efavirenz pharmacokinetics was characterized in AIDS Clinical Trials Group protocol A5279 (NCT01404312). The present analyses characterize pharmacogenetic interactions between these drugs, and with nevirapine.

Methods

A subset of HIV-positive individuals receiving efavirenz- or nevirapine-containing antiretroviral therapy in A5279 underwent pharmacokinetic evaluations at baseline, and again weeks 2 and 4 after initiating daily rifapentine plus isoniazid. Associations with polymorphisms relevant to efavirenz, nevirapine, isoniazid, and rifapentine pharmacokinetics were assessed.

Results

Of 128 participants, 101 were evaluable for associations with rifapentine and its active 25-desacetyl metabolite, 87 with efaviren

SUBMITTER: Haas DW 

PROVIDER: S-EPMC7655626 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature